Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

(2014) D Tural et al.   BRITISH JOURNAL OF CANCER

Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff

(2014) R. Duchnowska et al.   CLINICAL CANCER RESEARCH

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer

(2014) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

(2013) M Cizkova et al.   BRITISH JOURNAL OF CANCER

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2012) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab

(2011) J. D. Jensen et al.   ANNALS OF ONCOLOGY

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

(2011) R. Ghosh et al.   CANCER RESEARCH

Patterns of Recurrence after Breast-Conserving Treatment for Early Stage Breast Cancer by Molecular Subtype

(2011) Jae Myoung Noh et al.   Journal of Breast Cancer

High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer

(2010) Jiyoung Rhee et al.   BREAST CANCER RESEARCH AND TREATMENT

Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin

(2010) X. Huang et al.   CANCER RESEARCH

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

(2009) S-W Han et al.   BRITISH JOURNAL OF CANCER

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

(2008) D. L. Shattuck et al.   CANCER RESEARCH

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

(2008) H.-P. Kim et al.   MOLECULAR CANCER THERAPEUTICS